933 zoekresultaten voor “thijs werkt e2 80 99s discovery” in de Publieke website
-
Thijs BonenkampFaculteit Governance and Global Affairs
t.h.bonenkamp@fgga.leidenuniv.nl | +31 6 4810 5206
-
Thijs LoggenICT Shared Service Centre
m.m.loggen@issc.leidenuniv.nl | +31 71 527 5731
-
Thijs Rijkhoek
Faculteit Rechtsgeleerdheid
t.rijkhoek@law.leidenuniv.nl | +31 6 3091 8266
-
Thijs Lemaire
Faculteit Rechtsgeleerdheid
p.m.lemaire@law.leidenuniv.nl | +31 71 527 2727
-
Thijs AartsmaWiskunde en Natuurwetenschappen
aartsma@physics.leidenuniv.nl | +31 71 527 5967
-
Thijs StockmansWiskunde en Natuurwetenschappen
stockmans@strw.leidenuniv.nl | +31 71 527 2727
-
Thijs WittyFaculteit der Geesteswetenschappen
t.witty@hum.leidenuniv.nl | +31 71 527 2727
-
Thijs BiermanWiskunde en Natuurwetenschappen
t.v.bierman@biology.leidenuniv.nl | +31 71 527 2727
-
Thijs HoogenboomWiskunde en Natuurwetenschappen
hoogenboom@physics.leidenuniv.nl | +31 71 527 1897
-
Thijs VoskuilenWiskunde en Natuurwetenschappen
t.voskuilen@lic.leidenuniv.nl | +31 71 527 4516
-
Thijs BuurmanICT Shared Service Centre
t.m.buurman@issc.leidenuniv.nl | +31 71 527 2727
-
Thijs Porck
Online scriptiebegeleiding
-
Modern Drug Discovery
How are new drugs developed? This question is central to the Minor Modern Drug Discovery (MDD), which covers the entire trajectory from disease to drug molecule and vice versa. The various research groups involved offer a complementary and interdisciplinary perspective by connecting the diverse subjects…
-
Drug Discovery & Safety
In het onderzoeksprogramma Drug Discovery & Safety zijn we geïnteresseerd in de werkzaamheid en veiligheid van nieuwe medicijnen en nieuwe manieren om deze aspecten te bepalen. Daarvoor combineren we geavanceerde imaging en high-throughput screening technieken met computationele aanpakken zoals chem-…
-
Thijs Bos
Wiskunde en Natuurwetenschappen
j.m.bos@math.leidenuniv.nl | +31 71 527 2727
-
Thijs BoskerWiskunde en Natuurwetenschappen
t.bosker@cml.leidenuniv.nl | +31 71 527 4924
-
Thijs Vos
Faculteit der Sociale Wetenschappen
t.j.vos@fsw.leidenuniv.nl | +31 71 527 2727
-
Drug Discovery and Safety (MSc)
In deze opleiding ontwikkel je je onderzoek skills en verbreed je je kennis over de meest moderne en geavanceerde technieken die je nodig hebt als onderzoeker op het gebied van target finding en het ontwerp en de synthese van nieuwe geneesmiddelen.
-
Thijs PorckFaculteit der Geesteswetenschappen
m.h.porck@hum.leidenuniv.nl | +31 71 527 1611
-
Michiel ThijssenWiskunde en Natuurwetenschappen
thijssen@physics.leidenuniv.nl | +31 71 527 2727
-
Vivian ThijssenFaculteit Rechtsgeleerdheid
v.thijssen@law.leidenuniv.nl | +31 71 527 2727
-
Activity-based protein profiling in drug discovery
In the last decades, activity-based protein profiling (ABPP) has emerged as a powerful chemical tool that may aid the ever-challenging drug discovery process.
-
Inhibitor discovery of phospholipases and N-acyltransferases
In this thesis an activity-based probe was discovered that could visualize the activity of PLAATs. With an optimized gel-based ABPP assay in hand, screening of a compound library led to the discovery of alpha-ketoamides as a hit for PLAAT3.
-
Thijs de With
ICT Shared Service Centre
j.m.de.with@issc.leidenuniv.nl | +31 71 527 2727
-
Thijs van Veen
Universitair Facilitair Bedrijf
t.van.veen@ufb.leidenuniv.nl | +31 71 527 4231
-
Thijs van OschFaculteit Geneeskunde
m.j.p.van_osch@lumc.nl | +31 71 526 9111
-
Thijs van den Berg
Faculteit der Sociale Wetenschappen
t.s.van.den.berg@fsw.leidenuniv.nl | +31 71 527 2727
-
Thijs van DooremalenFaculteit Governance and Global Affairs
t.j.a.van.dooremalen@fgga.leidenuniv.nl | +31 70 800 9500
-
Thijs Brocades ZaalbergFaculteit der Geesteswetenschappen
t.w.brocades.zaalberg@hum.leidenuniv.nl | +31 71 527 2770
-
Discovery of antibiotics and their targets in multidrug-resistant bacteria
Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.
-
PhD candidate combinatorial drug discovery with macrocycles
Wiskunde en Natuurwetenschappen, Leiden Academic Centre for Drug Research (LACDR)
-
Discovery of selective diacylglycerol lipase β inhibitors
Diacylglycerol lipases (DAGLα and DAGLβ) are responsible for the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) in the brain and peripheral tissues. Selective DAGLβ inhibitors have been proposed as a potential treatment for inflammatory diseases with reduced potential for central…
-
Discovery of Reversible Monoacylglycerol Lipase Inhibitors
Monoacylglycerol lipase (MAGL) is the principal enzyme responsible for hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). MAGL inhibition provides several potential therapeutic opportunities, including anti-nociceptive, anti-inflammatory and anti-cancer activity.
-
Thijs van KolfschotenFaculteit Archeologie
t.van.kolfschoten@arch.leidenuniv.nl | +31 71 527 2640
-
Thijs Jan van Schie
Faculteit der Sociale Wetenschappen
t.j.van.schie@fsw.leidenuniv.nl | +31 71 527 3451
-
Thijs de BoerFaculteit Governance and Global Affairs
t.c.de.boer@fgga.leidenuniv.nl | +31 70 800 8206
-
Discovery and characterization of new glucosylated metabolites: pathophysiological consequences
Within this thesis the central stage is taken by the discovery and investigation of transglycosylation of sterols. First, investigation focuses on the development of a method to accurately detect and quantify glucosylated metabolites in biological materials.
-
Discovery of BUB1 kinase inhibitors for the treatment of cancer
The spindle-assembly checkpoint (SAC) is a safety mechanism which secures accurate chromosome segregation during mitosis.
-
Antibiotic Discovery: From mechanistic studies to target ID
The investigations described in this thesis lay out strategies aimed at advancing antibiotic research and development. The examples presented revolve around two main approaches: understanding drug-target interactions and target identification.
-
Discovery of FLT3 inhibitors for the treatment of acute myeloid leukemia
The disease acute myeloid leukemia (AML) is characterized by fast progression and low survival rates.
-
Microengineered Human Blood Vessels For Next Generation Drug Discovery
Heart failure is a major health care problem with high mortality.
-
Discovery of novel inhibitors to investigate diacylglycerol lipases and α/β hydrolase domain 16A
Promotor: H.S. Overkleeft, Co-promotor: M. van der Stelt
-
Proteins in harmony: Tuning selectivity in early drug discovery
This thesis describes the importance of being able to control the selectivity of potential drug candidates.
-
Harnessing zebrafish xenograft models for ocular melanoma treatment discovery
The aim of this thesis was to develop novel treatment strategies for different types of eye melanoma utilizing zebrafish models. We first establish orthotopic and ectopic xenograft models for uveal and conjunctival melanoma by engraftment of the immortalized cells derived from these tumors into zebrafish…
-
Causal Discovery from High-Dimensional Data in the Large-Sample Limit
Developing robust algorithms and theory for establishing cause-effect relationships from observational data that scale up to large data sets
-
Discovery of novel Antibiotics from Actinomycetes by Integrated Metabolomics & Genomics Approaches
Promotor: G.P. van Wezel, Co-promotor: Y.H. Choi
-
Genomics driven metabolomics novel strategies for the discovery and identification of secondary metabolites
Promotor: T. Hankemeier, Co-promotor: R.J. Vreeken
-
data into knowledge for intelligent decision-making in early drug discovery
Promotor: A.P.IJzerman Co-promotor: A. Bender
-
Knowledge discovery from patient forums: gaining novel medical insights from patient experiences
Patients share valuable advice and experiences with their peers in online patient discussion groups.
-
Image-based phenotypic screening for breast cancer metastasis drug target discovery
The main aim of this thesis was to unravel the signaling and regulatory networks that drive tumor cell migration during breast cancer metastasis.